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ABSTRACT
Objective: Previous studies have shown that
differential DNA methylation is associated with SLE
susceptibility. How DNA methylation affects the clinical
heterogeneity of SLE has not been fully defined. We
conducted this study to identify differentially
methylated CpG sites associated with nephritis among
women with SLE.
Methods: The methylation status of 428 229 CpG
sites across the genome was characterised for
peripheral blood cells from 322 women of European
descent with SLE, 80 of whom had lupus nephritis,
using the Illumina HumanMethylation450 BeadChip.
Multivariable linear regression adjusting for population
substructure and leucocyte cell proportions was used
to identify differentially methylated sites associated
with lupus nephritis. The influence of genetic variation
on methylation status was investigated using data from
a genome-wide association study of SLE. Pathway
analyses were used to identify biological processes
associated with lupus nephritis.
Results: We identified differential methylation of 19
sites in 18 genomic regions that was associated with
nephritis among patients with SLE (false discovery rate
q<0.05). Associations for four sites in HIF3A, IFI44 and
PRR4 were replicated when examining methylation data
derived from CD4+ T cells collected from an
independent set of patients with SLE. These
associations were not driven by genetic variation within
or around the genomic regions. In addition, genes
associated with lupus nephritis in a prior genome-wide
association study were not differentially methylated in
this epigenome-wide study. Pathway analysis indicated
that biological processes involving type 1 interferon
responses and the development of the immune system
were associated with nephritis in patients with SLE.
Conclusions: Differential methylation of genes
regulating the response to tissue hypoxia and
interferon-mediated signalling is associated with lupus
nephritis among women with SLE. These findings have
not been identified in genetic studies of lupus
nephritis, suggesting that epigenome-wide association
studies can help identify the genomic differences that
underlie the clinical heterogeneity of SLE.
INTRODUCTION
Lupus nephritis continues to cause substan-
tial morbidity and increased mortality for
individuals with SLE.1 The pathogenesis of
lupus nephritis involves intrarenal factors
such as immune complex formation and
deposition that lead to complement activa-
tion, as well as extra-renal factors including
genetic variants that predispose individuals
to a loss of tolerance, leading to autoanti-
body production against nuclear antigens.2
In a genome-wide association study of lupus
nephritis, the strongest genetic associations
with lupus nephritis were observed in the
PDGFRA-GSX2, SLC5A11 and ID4 regions.
These results indicated that genetic variants
outside of the major histocompatibility
complex and not previously associated with
SLE may have a greater influence in the
development of nephritis among patients
with SLE.3
More recently, DNA methylation, an epi-
genetic modification that influences gene
expression, has been implicated in the patho-
genesis of SLE. Two studies have indicated
that hypomethylation of interferon-regulated
genes in specific leucocyte subsets is asso-
ciated with SLE susceptibility.4 5 Our own
work has shown that among individuals with
SLE, hypomethylation of interferon-regulated
genes is associated with SLE-related autoanti-
body production.6 More recently, Coit et al7
also showed that, when compared with
healthy controls, CD4+ T cells from patients
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with SLE having nephritis showed a greater degree of
hypomethylation of interferon-regulated genes than
patients with SLE not having nephritis.
In this study, we build on our previous work by con-
ducting the largest genome-wide DNA methylation study
of lupus nephritis to date to identify genes and pathways
that are differentially methylated between SLE cases
with and without nephritis. We also examine the influ-
ence of genetic variation on the identified associations,
as well as methylation status of previously identified
lupus nephritis susceptibility genes among patients with
SLE with and without nephritis.
METHODS
Study subjects
The primary subject group for this study comprised 80
patients with SLE having nephritis and 245 patients with
SLE not having nephritis. All SLE cases were participants
of the University of California, San Francisco Lupus
Genetics Project and fulfilled at least four American
College of Rheumatology classification criteria for SLE.
To minimise confounding, all SLE cases were women of
European descent who had never smoked. Lupus neph-
ritis status was determined by medical record review.
SLE cases were considered to have lupus nephritis if
they fulfilled the renal classification criterion for SLE
(persistent proteinuria >0.5 gm/day or >3+ on urine dip-
stick or presence of cellular casts)8 or had a renal biopsy
showing lupus nephritis. A SLE case was considered not
to have lupus nephritis if no evidence of renal involve-
ment (eg, lacking haematuria and proteinuria) was iden-
tified on medical record review.
To replicate significant findings, we used the dataset
generated by Coit et al.7 This study assessed the methyla-
tion status of CD4+ T cells from 56 women with SLE. A
total of 28 women had lupus nephritis and 28 did not have
lupus nephritis. The two groups were ethnically matched
(17 European-American and 11 African-American indivi-
duals in each group). Additional details regarding this
study group are provided in Coit et al.7 To assess for
overlap between the two cohorts, we compared dates of
birth and recruitment site for the individuals in each
cohort, since genome-wide genetic data were not available
for individuals in the replication cohort. Only one birth
date was identical between the primary and replication
cohorts and the individuals with this date of birth were
recruited from different states within the USA. Thus, there
is likely no overlap between the two cohorts.
DNA methylation assessment
DNA methylation profiling of genomic DNA from per-
ipheral blood cells was performed using the Illumina
HumanMethylation450 BeadChip, as previously
described.6 This high-throughput platform assesses the
methylation status for ∼480 000 CpG sites in ∼23 000
genes and assesses methylation for sites in promoters, 50
and 30 regions, gene bodies, CpG islands, CpG island
shores and outside of CpG islands. For each site, the
primary output is the β-value, which is the ratio of the
methylated probe intensity to the overall probe intensity
and represents the proportion of DNA that is methy-
lated at that site (0=completely unmethylated, 1=com-
pletely methylated).
Prior to analysis, we performed extensive normalisation
and quality control measures. We removed sites which
had a low detection rate (p value for detection being
<0.05) in more than 20% of samples (289 CpG sites). All
samples met the detection threshold (<5% missing). To
normalise the data, background signal was subtracted
using the ‘noob’ method with the R package Methylumi.9
All sample mean normalisation was used to normalise
colour channels.10 The final normalisation step was
β-mixture quantile normalisation to normalise for differ-
ences between type 1 and type 2 probes on the Illumina
Infinium platform.11 We also removed cross-reactive
probes that may hybridise to more than one genomic
location (30969), polymorphic probes which are known
to contain a single nucleotide polymorphism (SNP) com-
monly found in populations of European ancestry
(29 027) and non-CpG rs SNP probes (65).12 We calcu-
lated correlations between replicate samples (38 dupli-
cate pairs) as a quality control measure and found
r2>0.98 for all sites across the duplicate pairs. From the
original dataset of 325 samples, we removed three
samples that were identified as outliers through principal
components analysis of methylation data. The final
dataset consisted of 428 229 CpG sites assessed in 322
individuals with SLE, of whom 80 SLE cases had nephritis
and 242 SLE cases did not have evidence of nephritis.
Methylation status of the 56 individuals used as the
replication cohort was also assessed using the Illumina
HumanMethylation450 BeadChip. Details regarding the
data processing for this group are provided in Coit et al.7
Cell population estimation
DNA methylation patterns can vary between different
blood cell populations.13 In order to account for cell-
type heterogeneity between samples, we calculated prin-
cipal components using the ReFACTor method14 to be
used in multivariable regression. ReFACTor is a
reference-free method that performs a principal compo-
nent analysis (PCA) on the subset of CpG sites that are
differentially methylated across different cell types to
adjust for variance due to cell-type heterogeneity. We
included the first two ReFACTor principal components
in regression analyses to adjust for cell heterogeneity
based on the examination of quantile-quantile plots for
inflation and deflation of p values and calculation of
genomic inflation factors (λ=0.90 for the first two princi-
pal components).
Population substructure
Population substructure may confound the associations
between lupus nephritis and methylation since genetic
ancestry may be associated with both methylation15 and
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disease status. Therefore, a genetic PCA was computed
in EIGENSTRAT, as previously described,6 using SNP
data generated with the Illumina HumanHap500 and
ImmunoChip genotyping platforms. The first principal
component was included in multivariable linear regres-
sion analysis to adjust for confounding due to popula-
tion substructure.
Statistical analyses
All regression analyses were conducted in R (V.3.2.2) (R
Core Team. R: A Language and Environment for
Statistical Computing [program], Vienna, Austria, 2015.
http://www.R-project.org/). For each of the 428 229
CpG sites under study, multivariable linear regression
was used to determine the association between lupus
nephritis status and methylation. For these regression
models, methylation β-values were used as the outcome
and lupus nephritis status was the primary predictor.
Disease duration, the first genetic principal component
and the first two ReFACTor principal components were
included as covariates. The Benjamini-Hochberg false
discovery rate (FDR) method16 was used to adjust for
multiple comparisons, with an FDR q-value of <0.05 con-
sidered statistically significant.
All sites with an FDR q<0.05 (n=19) were further
examined in an independent dataset generated by Coit
et al7 for replication. For this dataset, association with
lupus nephritis was determined using Wilcoxon
rank-sum tests (STATA V.13.1, College Station, Texas,
USA), with a stringent Bonferroni-corrected threshold
of p<0.0026 (0.05/19) considered statistically significant.
To assess the role of genetic variation on the identified
associations between DNA methylation sites and lupus
nephritis, we used SNP data available from 264 of the study
subjects from a genome-wide association study of SLE.17
We identified SNPs on the Illumina HumanHap500
BeadChip located 500 kb upstream and downstream of the
associated CpG sites and analysed SNPs with a minor allele
frequency of >0.05. For each CpG, we ran multivariable
regression analyses as previously described and included
the SNPs in the vicinity of the CpG as a covariate, assuming
an additive model. Each CpG-SNP pair was analysed separ-
ately. FDR q-values were calculated based on the number of
CpG-SNP pairs for a CpG site, with FDR q<0.05 considered
statistically significant.
We further examined if methylation of previously iden-
tified lupus nephritis susceptibility genes3 was associated
with nephritis among SLE cases. We examined the CpG
sites on the HumanMethylation450 BeadChip that were
within 5000 bp upstream and downstream of the genes.
We readjusted the p values using FDR correction for this
smaller subset of CpG sites from the final model in
order to determine if any of these sites were differen-
tially methylated between the two nephritis subgroups.
Last, we conducted a pathway analysis using the
gometh() function in missMethyl R package to deter-
mine if differential methylation of genes in particular
pathways were associated with lupus nephritis. This
analysis used 1000 CpGs with the strongest evidence of
association with lupus nephritis based on p values from
multivariable regression models (without SNPs). The
missMethyl package was developed specifically for the
Illumina HumanMethylation450 array and the gometh()
function tests for Gene Ontology enrichment for signifi-
cant CpGs, taking into account the different number of
methylation probes per gene on the array.
RESULTS
The clinical characteristics of the 322 SLE cases exam-
ined in this study are presented in table 1. To minimise
confounding by sex, race/ethnicity and smoking status,
all study participants in the primary dataset were women
of European descent who never smoked. SLE cases with
nephritis had a longer disease duration and, not unex-
pectedly, a higher frequency of autoantibody positivity.
Of the 50 SLE cases with nephritis who underwent renal
biopsy and had pathology reports available for review, 32
(64%) had class III/IV (proliferative) nephritis and 10
(20%) had class V (membranous) nephritis.18
We first performed a genome-wide assessment of dif-
ferential DNA methylation associated with lupus neph-
ritis. Results from the multivariable regression analysis
Table 1 Characteristics of the 322 patients with SLE in
this study
Characteristic
SLE with
nephritis (n=80)
SLE without
nephritis (n=242)
Age at blood draw,
mean years (SD)
43.20 (12.86) 46.36 (13.18)
Disease duration,
mean years (SD)
16.25 (10.11) 10.69 (8.02)
ACR classification criteria for SLE, n (%)
ANA positivity 76 (95.0) 229 (94.6)
Malar rash 43 (53.8) 110 (45.5)
Discoid rash 3 (3.8) 7 (2.9)
Oral ulcers 19 (23.8) 80 (33.1)
Photosensitivity 59 (73.8) 201 (83.1)
Arthritis 57 (71.3) 186 (76.9)
Serositis 25 (31.3) 69 (28.5)
Neurological
disorder
11 (13.8) 19 (7.9)
Haematological
disorder
64 (80.0) 151 (62.4)
Immunological
disorder
67 (83.8) 148 (61.2)
SLE-related autoantibodies, n (%)
Anti-dsDNA 56 (70.0) 98 (40.5)
Anti-SSA/Ro 24 (31.6*) 62 (25.6*)
Anti-SSB/La 10 (13.3*) 23 (9.5*)
Anti-Sm 14 (18.7*) 23 (9.5*)
Anti-RNP 18 (24.0*) 38 (15.7*)
*Percentages are not based on all 322 participants due to missing
values.
ACR, American College of Rheumatology; ds, double-stranded;
RNP, ribonucleoprotein; SSA, Sjögren’s syndrome related antigen
A; SSB, Sjögren’s syndrome related antigen B.
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are shown in figure 1. The methylation status of 19 CpG
sites had statistically significant evidence of association
with lupus nephritis (FDR q<0.05) after adjusting for
disease duration, population substructure and periph-
eral blood cell heterogeneity (table 2). Eight sites were
more methylated in patients with SLE having nephritis
compared with those without nephritis, with the differ-
ence in methylation ranging from 1.4% to 6.4%. Among
these sites, the most hypermethylated site was
cg23510764 on chromosome 5. Eleven sites were less
methylated in SLE cases with nephritis compared with
those without nephritis, with the difference in methyla-
tion ranging from −2.3% to −12.4% between SLE cases
with and without nephritis. The most hypomethylated
site among these 11 sites was cg05552874 located in
IFIT1.
We then sought replication for these findings using
DNA methylation data generated with the same platform
from CD4+ T cells from 56 patients with SLE.7 Out of
the 19 sites we identified in our initial analyses, methyla-
tion of four sites in or near hypoxia-inducible transcrip-
tion factor (HIF)3A, interferon-induced protein 44
(IFI44) and lacrimal proline-rich protein 4 (PRR4) in
CD4+ T cells showed evidence of association with lupus
nephritis in Wilcoxon rank-sum tests (p<0.0026), as
shown in table 2.
Next, we examined whether methylation of 15 previ-
ously identified lupus nephritis susceptibility genes3 was
associated with lupus nephritis, to determine if epigen-
etic associations are driven by genetic variation. We iden-
tified 12 794 CpG sites that were located within 5000 bp
upstream or downstream of the lupus nephritis suscepti-
bility genes for this analysis. Even with readjustment of
the FDR q-value for only these sites, no site showed evi-
dence of association with lupus nephritis (FDR q>0.1,
data not shown).
To determine if the associations between methylation
status and lupus nephritis could be confounded by
genetic variation (ie, that genetic variation influences
both the development of lupus nephritis and extent of
methylation at a site), we used genome-wide SNP data
available on 264 study subjects who had been previously
genotyped with the Illumina HumanHap500 BeadChip.
SNPs within 500 kb of the associated CpG site were
included in multivariable regression analyses. Online
supplementary table S1 shows the total number of SNPs
studied for each CpG site and the number of SNPs with
FDR q<0.05 in multivariable regression modelling. SNPs
in or near HELZ2, HIF3A, MIR-29B-2/LOC148696 and
PRR4 showed evidence of association with methylation
(FDR q<0.05) but did not substantially alter the associ-
ation between methylation and lupus nephritis status
(see online supplementary table S2). These findings
suggest that the observed associations between methyla-
tion status and lupus nephritis do not appear to be
driven by genetic variation of these genes.
We also examined whether these results could be con-
founded by medication exposure. While we were unable
to adjust for medication dose at sample collection (data
not available), we ascertained previous exposure to pred-
nisone, hydroxychloroquine, azathioprine, methotrex-
ate, mycophenolate mofetil and cyclophosphamide by
medical record review and patient questionnaire. While
medication exposure did differ between those with and
without lupus nephritis as expected (eg, higher preva-
lence of mycophenolate mofetil and cyclophosphamide
Figure 1 Manhattan plot of DNA methylation sites associated with lupus nephritis based on a multivariable linear regression.
The red line shows a false discovery rate (FDR) cut-off of significance level p<2.1E-06. Significant CpG sites are highlighted in
green.
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Table 2 Differentially methylated CpG sites associated with nephritis in women with SLE
Primary dataset from whole blood
(n=80 SLE with nephritis, n=242
SLE without nephritis)
Replication dataset from CD4+T cells (n=28 SLE with nephritis,
n=28 SLE without nephritis)
CpG Chr
Position
(hg19) Gene(s) β*
Regression p
value
FDR
q-value
Median SLE
with nephritis
Median SLE
without nephritis
Median
difference
Wilcoxon p
value
cg15262954 20 62198871 HELZ2 0.014 2.84E-08 0.012 0.307 0.213 0.094 0.25
cg19168338 16 4465730 CORO7 0.016 2.89E-07 0.035 0.323 0.318 0.005 0.31
cg00356916 1 116256617 CASQ2 0.015 4.01E-07 0.035 0.619 0.604 0.015 0.67
cg01079652 1 79118190 IFI44 −0.086 4.96E-07 0.035 0.687 0.814 −0.127 0.0013
cg05883128 4 169239130 DDX60 −0.093 5.30E-07 0.035 0.124 0.151 −0.027 0.16
cg25114611 6 35696869 FKBP5;
LOC285847
−0.026 5.46E-07 0.035 0.381 0.403 −0.022 0.024
cg22891070 19 46801641 HIF3A −0.094 5.69E-07 0.035 0.700 0.807 −0.106 0.0001
cg05552874 10 91153142 IFIT1 −0.124 7.87E-07 0.04 0.516 0.691 −0.175 0.0069
cg18468088 6 35490817 No gene within
5 kb
−0.026 8.91E-07 0.04 0.104 0.13 −0.026 0.33
cg00791854 1 154392069 IL6R 0.023 1.11E-06 0.04 0.482 0.474 0.008 0.78
cg23510764 5 166419954 No gene within
5 kb
0.064 1.17E-06 0.04 0.773 0.789 −0.016 0.0096
cg02812482 19 13974981 No gene within
5 kb
0.023 1.19E-06 0.04 0.4 0.396 0.004 0.95
cg04845871 1 207996318 MIR-29B-2†,
LOC148696†
0.019 1.22E-06 0.04 0.363 0.353 0.010 0.074
cg23256579 12 11002402 PRR4 −0.05 1.41E-06 0.041 0.661 0.712 −0.051 0.0015
cg16672562 19 46801671 HIF3A −0.092 1.55E-06 0.041 0.725 0.840 −0.114 0.0001
cg16032408 3 14466410 SLC6A6 −0.025 1.61E-06 0.041 0.342 0.337 0.005 0.62
cg13437525 12 51318486 METTL7A‡ −0.023 1.67E-06 0.041 0.256 0.284 −0.028 0.12
cg14519664 9 20356458 MLLT3 0.037 1.71E-06 0.041 0.243 0.236 0.007 0.34
cg10959651 2 7018019 RSAD2 −0.054 2.11E-06 0.048 0.105 0.132 −0.027 0.069
Associations with bolded sites were replicated in CD4+ T cells.
*β represents the difference in methylation between SLE cases with nephritis and SLE cases without nephritis adjusted for disease duration, population substructure and mixed cell populations.
Positive values indicate that the site is more methylated in SLE cases with nephritis, while negative values indicate the site in less methylated in SLE cases with nephritis.
†Found within 5 kb downstream of the site.
‡Found within 5 kb upstream of the site.
FDR, false discovery rate.
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use in patients with SLE having lupus nephritis com-
pared with patients with SLE not having nephritis),
adjusting for previous medication exposure did not sig-
nificantly alter the associations between methylation of
19 sites in table 2 and lupus nephritis (data not shown).
Last, we performed a pathway analysis to determine if
genes with evidence of differential methylation associa-
tions with lupus nephritis represent particular biological
pathways. Using Gene Ontology as the basis for this ana-
lysis, the top 1000 CpG sites with the strongest evidence
of association by regression p value were studied.
Thirty-three Gene Ontology groups were found to be
over-represented in the top 1000 CpG sites. The 10 most
significantly associated Gene Ontology groups as deter-
mined by FDR q-value are shown in table 3. These
results indicate that differential methylation of genes
involved in interferon signalling and host response path-
ways show the strongest evidence of association with
lupus nephritis among individuals with SLE.
DISCUSSION
In this study, we present the largest genome-wide assess-
ment of DNA methylation in lupus nephritis to date. In
our initial samples obtained from whole blood, we identi-
fied evidence for differential methylation of 19 sites in 18
genomic regions associated with lupus nephritis.
Association with four sites in HIF3A, IFI44 and PRR4 were
subsequently replicated when we examined DNA methy-
lation of CD4+ T cells from an independent set of women
with SLE. Observed methylation associations are not
driven by DNA sequence variation surrounding the asso-
ciated CpG site. In pathway analyses, differential methyla-
tion of interferon signalling and host defence genes had
the strongest evidence of association with lupus nephritis.
Two of the replicated associations, cg22891070 and
cg16672562, are located approximately 200 bp upstream
from the transcription start site or within the gene body
of HIF3A, depending on the gene transcript. HIF3A
encodes the third isoform of the α subunit of the HIF,
which can activate the transcription of over 100 genes
involved with the cell’s response to hypoxia, including
genes involved in angiogenesis, glucose metabolism and
cell proliferation. The role of HIF3A is less well deli-
neated compared with the two other isoforms, in part
because HIF3A mRNA undergoes alternative splicing,
with at least seven known variants. Specific variants of
HIF3A have been shown to act as a negative regulator of
HIF1 and HIF2, while overexpression of other variants
upregulate specific HIF target genes.19 Hypermethylation
(instead of the hypomethylation observed in this study)
of these CpG sites has been associated with increased
body mass index.20 Previous epidemiological studies have
suggested that increased body mass index is associated
with chronic kidney disease,21 even among patients with
SLE.22 Thus, it is not evident that the associations
between lupus nephritis and hypomethylation of HIF3A is
due to confounding by body mass index. Chronic
hypoxia in the tubulointerstitium of the kidney is pro-
posed to be a common pathway that leads to end-stage
renal disease and thus HIF plays a critical pathophysio-
logical role in this process. HIF is also being studied as a
target for therapies to prevent progression of chronic
kidney disease.23 Our findings for HIF3A are novel, since
neither genetic variation nor methylation of HIF genes
has been associated with SLE or specific SLE-related sub-
phenotypes in prior studies. Hypomethylation of
HIF-related genes may contribute to the development of
lupus nephritis or occur as the result of organ damage
from nephritis in patients with SLE. In either scenario,
Table 3 The top 10 Gene Ontology groups represented by the 1000 CpG sites with the strongest evidence of association
with lupus nephritis
Gene Ontology
accession # Group/term
No. of
genes in
group
No. of genes
represented in the
top 1000 CpG sites
p Value based on the
number of differentially
expressed genes FDR
GO:0034340 Response to type 1
interferon
76 17 1.77E-10 3.68E-06
GO:0060337 Type 1 interferon signalling
pathway
72 16 6.80E-10 4.72E-06
GO:0071357 Cellular response to type 1
interferon
72 16 6.80E-10 4.72E-06
GO:0002376 Immune system process 2544 138 2.01E-08 1.05E-04
GO:0051607 Defence response to virus 315 30 1.04E-07 4.32E-04
GO:0098542 Defence response to other
organisms
521 38 2.09E-07 7.25E-04
GO:0009615 Response to virus 396 34 5.09E-07 0.00151
GO:0065007 Biological regulation 10877 443 1.09E-06 0.00283
GO:0045071 Negative regulation of viral
genome replication
48 10 1.75E-06 0.00405
GO:0006952 Defence response 1758 94 2.19E-06 0.00455
FDR, false discovery rate; GO, gene ontology.
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therapy targeting the HIF pathway may provide a novel
strategy to decrease the progression of kidney damage for
patients with lupus nephritis.
We also replicated an association between lupus neph-
ritis and hypomethylation of cg01079652, which is
located within the gene body of IFI44. While the role of
IFI44 is not completely defined, some evidence suggests
that this interferon-inducible gene acts as a suppressor
of viral replication.24 In the study by Coit et al,7 hypo-
methylation of this CpG site was identified when com-
paring SLE cases with nephritis with healthy controls
and was not identified when SLE cases without nephritis
were compared with healthy controls. In a study by
Absher et al,5 this site was significantly hypomethylated
in CD4+ T cells, CD19+ B cells and CD14+ monocytes
when comparing patients with SLE with healthy con-
trols. Of note, hypomethylation of IFI44L, a paralog of
IFI44, was found to be associated with SLE,4 SLE-related
autoantibody production6 by our group and more
recently was shown to be a biomarker for SLE when
compared with individuals with other autoimmune dis-
eases and healthy controls.25
The third replicated association was with cg23256579,
which occurs ∼1500 bases upstream or within the body
of PRR4, depending on the transcript variant. PRR4 has
been identified as a potential biomarker of the dry-eye
syndrome.26 Read-through transcription also exists
between this gene and the upstream gene PRH1
(proline-rich protein HaeIII subfamily 1). This tran-
script is a candidate for nonsense-mediated mRNA
decay and is unlikely to produce a protein product. No
previous associations between methylation of this site
and SLE-related phenotypes have been reported.
We also found evidence of differential methylation of
15 CpG sites near or within HELZ2, COR07, CASQ2,
DDX60, FKBP5, IFIT1, IL6R, MIR-29B-2b, SLC6A6,
METTL7A, MLLT3 and RSAD2 in whole blood, which
did not meet our stringent threshold for replication in
the CD4+ T-cell dataset. Of the 15 sites, 13 showed con-
cordant direction of differential methylation between
the initial and replication cohorts. Two sites, located in/
near in IFIT1 and FKBP5 had suggestive statistical evi-
dence of association in the replication cohort (p=0.0069
and p=0.024, respectively). While a lack of replication
may indicate false-positive results, these findings may not
have replicated due to insufficient statistical power given
the small sample size of the replication dataset, the dif-
ferences in race/ethnic compositions between the two
sample groups or because the differential methylation
observed for these sites are not driven by CD4+ T cells.
Differential methylation of these genes in other cell
populations may be more relevant for the development
of lupus nephritis. Differential methylation of sites near
or within IFIT1 and RSAD2 have been previously asso-
ciated with SLE-related autoantibody production,6 while
differential methylation of the associated sites in HELZ2
(also known as PRIC285), DDX60, IFIT1, CASQ2, IFI44
and FKBP5 has been observed in specific leucocyte
subsets among patients with SLE compared with healthy
controls.4 5 Thus, while the p value for association with
lupus nephritis for these sites did not meet our thresh-
old for replication, methylation of many of these sites is
likely associated with SLE-related outcomes given their
previously identified association with SLE susceptibility.
Previously, we showed that methylation of CpG sites in
11 genes was associated with anti-double-stranded (ds)
DNA and SLE-related autoantibody production and 7
out of the 11 genes either induced or regulated type 1
interferon signalling. Given the strong correlation
between anti-dsDNA autoantibodies and lupus nephritis,
we expected to see interferon-related genes dominate
the list of statistically significant results. However, among
the 18 genomic regions with the strongest statistical evi-
dence of association with lupus nephritis in this study,
only four are known to be induced by type 1 interferon
(IFI44, IFIT1, DDX60 and RSAD2). Thus, in contrast to
SLE-related autoantibodies, the majority of the most sig-
nificantly associated methylation sites with lupus neph-
ritis are not in interferon-related genes. This finding
may represent a key pathophysiological difference
between autoantibody production and lupus nephritis.
However, interferon-related genes do likely influence
the development of lupus nephritis to some extent,
given the results of the pathway analyses.
Associations with DNA methylation and lupus neph-
ritis were also examined by Coit et al.7 However, their
results are not directly comparable with ours given dif-
ferences in study design—instead of performing a
within-SLE case analysis as in this study, SLE cases with
and without nephritis were compared with healthy con-
trols. However, similar to our findings, Coit et al
observed that interferon-related genes were even less
methylated in SLE cases with lupus nephritis than SLE
cases without nephritis when both groups were com-
pared with healthy controls.
Strengths of our study include the large sample size and
selection of SLE cases to minimise confounding due to
sex, ethnicity and smoking status. Unlike many studies of
DNA methylation, we were able to adjust for differences in
genetic ancestry among the SLE cases using genome-wide
SNP data. Our analyses also accounted for disease duration
to mitigate the effect of the disease itself on DNA methyla-
tion status and the potential misclassification of lupus
nephritis status. Last, we employed a reference-free
method to estimate and adjust for potential differences in
the leucocyte composition between study subjects.
Limitations of our study include its cross-sectional
nature. Thus, we are unable to determine if these
changes in methylation occur prior to or after the devel-
opment of lupus nephritis. However, the identification
of novel disease-relevant pathways provides insights into
the pathogenesis and progression of lupus nephritis,
even if these pathways are not the biological processes
that initiate disease. In addition, the body mass index of
the participants was not available to include in our ana-
lyses. Last, we examined DNA from peripheral blood
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cells since it can be easily collected in a clinical setting
for the development of future clinical tests and is readily
available from our study collection. Therefore, we could
not assess which specific leucocyte population harbours
these DNA methylation changes. However, our findings
for CpG sites within or near HIF3A, PRR4 and IFI44
were replicated in a dataset derived from CD4+ T cells,
which suggests that methylation changes in CD4+ T cells
contribute to the differences we identified in our study.
In summary, we have shown that hypomethylation of
CpG sites in or near tissue hypoxia and interferon sig-
nalling response genes is associated with lupus nephritis.
Our results support the premise that genetic and epi-
genetic variations can be independently associated with
disease manifestations. Thus, epigenome-wide associ-
ation studies can identify novel pathways associated with
disease manifestations not identified by genome-wide
association studies and can provide complementary
insight into the pathogenesis and progression of genetic-
ally complex autoimmune diseases.
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